Liver assessment in a hypervascular primary
Hepatic arterial phase evidence base; LI-RADS technical requirements; NCCN sarcoma/melanoma stagingThe question is the LIVER in a primary whose hepatic deposits are hypervascular — neuroendocrine above all, and renal cell. A portal-venous-only CT is the wrong study for that question and reports as a false negative, because the window in which the lesion is visible closes before the standard staging phase opens. The card exists to teach why the late arterial acquisition is not optional where it is needed, and equally why it is not a licence to add two abdominal passes to every staging CT.
Known or suspected hypervascular primary requiring liver assessment: baseline staging, restaging, or a rising tumour marker with a previously negative portal-venous CT.
Referenced decision support — confirm against your local protocol.
Decision support, not a directive. Protocols and timings shown are typical published ones — your local protocol takes precedence, and the vetting radiologist decides.
- The late arterial acquisition is the only phase in which a hypervascular deposit is brighter than the liver around it. Published CT series show additional metastases found only on the arterial phase in a meaningful minority of patients, and lesions visible on no other phase in a small but real subset. The portal venous acquisition is still acquired, because it stages the rest of the abdomen and pelvis and because some deposits show washout rather than persistent enhancement; the unenhanced series provides the baseline that separates true enhancement from intrinsic density such as calcification or haemorrhage. Three phases here are not defensive imaging — each answers a different question.
Nothing needs resolving before this goes ahead. Routine checks below are owned downstream.
How was this decided?
- pathwaystandard — Adults — hypervascular primary
- rulerule-contrast-reaction-premed — Prior contrast reaction and elective premedication; checked by Nurse before the scan
- rulerule-metformin — Metformin and iodinated contrast; checked by Radiographer at the scanner
- rulerule-paeds-dose — Child-sized technique and contrast dose; checked by Radiographer at the scanner
- rulerule-pregnancy-ionising — Pregnancy status before an ionising exposure; checked by Radiographer at the scanner
- rulerule-renal-iodinated — Kidney function and intravenous iodinated contrast; checked by Radiographer at the scanner
- rulerule-iv-access — Intravenous access adequate for the planned injection; checked by Radiographer at the scanner
Decision support only. Local protocol takes precedence.
Handled at the scanner(4)nothing for you to do
Settled and owned downstream. Each returns to a radiologist only on the stated trigger.
- Metformin and iodinated contrastConfirm whether the patient takes metformin or a metformin-containing combination, and if so whether ACR Category II applies (eGFR below 30, known or suspected AKI, or an arterial catheter study likely to cause renal embolisation). If Category I — that is, no AKI and eGFR at or above 30 — no action of any kind is needed.Radiographer at the scannerAt the scannerFlags back if: The patient takes metformin AND meets ACR Category II — eGFR below 30 mL/min/1.73 m2, known or suspected acute kidney injury, or an arterial catheter procedure with likely renal arterial embolisation. Metformin plus a normal or mildly reduced eGFR is explicitly NOT a flag-back: there is no need to stop metformin before or after intravenous iodinated contrast in Category I patients, and no need to re-check creatinine afterwards.
- Child-sized technique and contrast doseConfirm that a size- or weight-based protocol is selected — child-sized kV and mAs against size-based diagnostic reference ranges — and that contrast volume is calculated by weight rather than taken from an adult default. Weight-based iodinated contrast volumes of roughly 1.5–2.0 mL/kg are widely used in paediatric CT.Radiographer at the scannerAt the scannerFlags back if: No paediatric or size-based protocol exists on the scanner for the requested examination, or the requested coverage or number of phases exceeds what the clinical question needs — for example a multiphase study where a single phase answers it, or whole-body coverage for a focal question.
- Pregnancy status before an ionising exposureMake the pregnancy enquiry immediately before the exposure and record the answer. In the UK this is a statutory operator duty discharged at the time of exposure under the employer’s written procedures required by IR(ME)R 2017 — it is not something the vetting radiologist can perform or pre-empt, and a request is complete without it.Radiographer at the scannerAt the scannerFlags back if: The patient states that she is, or may be, pregnant AND the uterus is in or near the primary beam. The exposure is then paused for re-justification by the IR(ME)R practitioner before it proceeds.
- Intravenous access adequate for the planned injectionSite and test a cannula that supports the protocol flow rate, preferring an antecubital or large forearm vein, and observe the injection for extravasation. A 20-gauge or larger cannula is preferred for flow rates of 3 mL/s or more.Radiographer at the scannerAt the scannerFlags back if: No cannula can be sited that supports the protocol flow rate — for example only a 22-gauge hand or foot cannula for a CT angiogram needing 4–5 mL/s; or the only available access is a central line or port that is not labelled power-injectable; or an extravasation occurs.
Worth asking the referrer (1)
None of these hold the request up. They sharpen the protocol or the plan that follows.
- Which primary, and is it known to be hypervascular?It is the entire basis for adding the arterial acquisition; a hypovascular primary should be staged on the standard single-phase protocol instead.
Pathways
Big forks are separate pathways; the first whose conditions match is the one used.
Adults — hypervascular primary
Matches your inputsDefault| Role | Study & protocol | Why this answers the question |
|---|---|---|
| First line | CT Liver — Multiphase CT Liver — Triphasic (Unenhanced, Late Arterial, Portal Venous) usually appropriate | The late arterial acquisition is the only phase in which a hypervascular deposit is brighter than the liver around it. Published CT series show additional metastases found only on the arterial phase in a meaningful minority of patients, and lesions visible on no other phase in a small but real subset. The portal venous acquisition is still acquired, because it stages the rest of the abdomen and pelvis and because some deposits show washout rather than persistent enhancement; the unenhanced series provides the baseline that separates true enhancement from intrinsic density such as calcification or haemorrhage. Three phases here are not defensive imaging — each answers a different question. |
| Problem solving | MRI Liver MRI Liver — multiphase with extracellular gadolinium | More sensitive than CT for small hypervascular deposits because diffusion-weighted imaging and the T2 signature add detection independent of the enhancement window, which is unforgiving on CT. The right escalation when the CT is negative and the biochemistry is not, and the right first study when the liver is the sole determinant of resectability. |
| First line | CT Chest CT Chest — Contrast-Enhanced (Venous Phase) | Thoracic staging is unchanged by the hypervascular question and is acquired in the venous phase as usual. Only the liver acquisition needs the arterial timing. |
Pitfalls
- Accepting a plain portal-venous CT abdomen for a neuroendocrine, renal or melanoma primary. This is the classic false negative of oncological CT and the single commonest reason a hypervascular liver burden is discovered late.
- Scanning the arterial phase too early. An early arterial acquisition opacifies arteries but leaves the parenchyma and the lesion both unenhanced; the phase needed is late arterial, when the portal vein is opacified but the hepatic veins are not.
- Reading transient perfusion abnormality on the arterial phase as metastatic disease. Anything seen on the arterial phase alone, with no correlate on the unenhanced or venous series and no mass effect, deserves scepticism.
- Assuming every neuroendocrine deposit is hypervascular. A minority, particularly higher-grade tumours, are hypovascular and are seen best on the venous series — which is why the venous phase stays in the protocol.
- Dropping the unenhanced series to save dose, then being unable to tell a calcified treated deposit from an arterially enhancing live one.
- Applying this card as a rule about primaries rather than about a question. The arterial acquisition earns its dose when the liver is the determinant of management; bolting it onto a routine staging CT for a sarcoma, a melanoma or a thyroid primary is two extra abdominal exposures with no yield, and in the thyroid case an iodine load that delays radioiodine therapy.
Priors — what to pull first
- Check the phase used on every prior CT before calling disease new. A deposit that "appeared" between two scans has often simply had an arterial phase acquired for the first time.
- Where a previous study was single-phase, say so explicitly in the report so that the comparison is not read as progression.
What makes a good request
- Hypervascular metastases are supplied almost entirely by the hepatic artery, so they peak while the liver parenchyma — supplied mostly by the portal vein — is still barely enhanced. By the portal venous phase the parenchyma has caught up and the lesion becomes isodense. The window in which the lesion is visible closes before the standard staging phase opens.
- A previous "normal" portal-venous staging CT in a patient with a neuroendocrine primary and rising chromogranin is not reassurance; it is an inadequate protocol, and repeating it will produce the same answer.
- Somatostatin receptor PET-CT is the functional counterpart for neuroendocrine primaries and detects disease that is occult on CT. It is not represented in this vocabulary and must be requested outside this pathway.
- The list of primaries whose hepatic deposits CAN be hypervascular is not the same as the list whose ROUTINE STAGING requires a multiphase liver, and conflating the two is how this card gets misused. Neuroendocrine tumours and renal cell carcinoma are the two where the arterial acquisition is load-bearing at baseline. Soft tissue sarcoma stages to the chest, because lung is the metastatic site, and routing it to a triphasic liver adds two abdominal passes with no yield. Melanoma is staged with FDG PET-CT or single-phase CT. Differentiated thyroid carcinoma is staged with neck ultrasound and radioiodine imaging, and an iodine load there delays radioiodine therapy for weeks — so the multiphase CT is not merely unnecessary in that group, it is harmful. This card is for the patient in whom the liver is the determinant of management.
Scoring this once it is done
The classification and risk tools this question ends in.
How these studies are acquired
Contrast, phases and timing for every study on the pathways above.
Confirm locally
- CT Liver — Triphasic (Unenhanced, Late Arterial, Portal Venous): timings are typical — confirm against local protocol.
- Timings, contrast volumes and rates above are typical published values. Your department's protocol, scanner and patient population decide the actual numbers.
- Safety thresholds and premedication policy follow local policy where it differs from the cited guidance.
References
- Hypervascular liver metastases: do unenhanced and hepatic arterial phase CT images affect tumour detection? (Radiology) · Primary literature
- MR imaging of hepatic metastases caused by neuroendocrine tumours: comparing four techniques (AJR) · Primary literature
- LI-RADS technical requirements for CT, MRI and contrast-enhanced ultrasound · ACR LI-RADS
- NCCN Clinical Practice Guidelines in Oncology — Soft Tissue Sarcoma and Cutaneous Melanoma: staging imaging is chest-dominant in sarcoma and PET-CT or single-phase CT in melanoma · Other
- ACR Manual on Contrast Media — iodinated contrast saturates the thyroid iodine pool and delays radioiodine imaging and therapy · ACR Contrast Manual
- ACR Manual on Contrast Media — premedication regimens (elective oral prednisone 50 mg at 13/7/1 h plus diphenhydramine 50 mg at 1 h; methylprednisolone 32 mg at 12 and 2 h; accelerated IV hydrocortisone 200 mg or methylprednisolone 40 mg every 4 h; regimens under 4–5 h lack evidence of efficacy) · ACR Contrast Manual
- Management and Prevention of Hypersensitivity Reactions to Radiocontrast Media: A Consensus Statement from the ACR and the AAAAI. J Allergy Clin Immunol Pract, 2025. · Primary literature
- Schabelman E, Witting M. The relationship of radiocontrast, iodine and seafood allergies: a medical myth exposed. J Emerg Med. · Primary literature
- CAR/CSACI Practice Guidance for Contrast Media Hypersensitivity (2025) · Other
- ESUR Contrast Media Guidelines v10.0 / van der Molen AJ et al., Eur Radiol 2018 — stop metformin from the time of contrast administration if eGFR is below 30 mL/min/1.73 m2; patients above 30 without AKI continue normally. · ESUR
- Image Gently — child-sizing the CT dose; size-based protocols and accreditation of paediatric CT dose indices · Image Gently
- Strauss KJ et al. Image Gently: Ten Steps You Can Take to Optimize Image Quality and Lower CT Dose for Pediatric Patients (AJR) · Image Gently
- AAPM Pediatric Routine Abdomen and Pelvis CT Protocol — size-based technique parameters · Other
- The Ionising Radiation (Medical Exposure) Regulations 2017 (SI 2017/1322) — Schedule 2 requires written procedures for making enquiries of individuals of childbearing potential to establish whether they are or may be pregnant or breastfeeding; the operator is responsible for the practical aspects they carry out. · RCR
- Society of Radiographers — The impact of IR(ME)R 2017 / IR(ME)R (NI) 2018 on pregnancy checking procedures · RCR
- ACR-SPR Practice Parameter for Imaging Pregnant or Potentially Pregnant Patients with Ionizing Radiation — Fetal dose <50 mGy not shown to increase risk of pregnancy loss or malformation; attributable cancer risk approximately 0.4% per 10 mGy · Other
- IAEA Radiation Protection of Patients — pregnancy enquiry is not needed for examinations in which the uterus is remote from a properly collimated primary beam (head, extremities) · Other
- Davenport MS et al. Use of Intravenous Iodinated Contrast Media in Patients with Kidney Disease: Consensus Statements from the ACR and the National Kidney Foundation. Radiology 2020. — Prophylaxis indicated for AKI or eGFR <30 not on maintenance dialysis; may be considered case-by-case at eGFR 30–44 · ACR/NKF consensus
- ESUR Contrast Media Safety Committee Guidelines v10.0 — post-contrast acute kidney injury, risk factors and hydration — ESUR retains broader screening triggers (including age >60, diabetes, hypertension, single kidney) than the ACR/NKF targeted list — a genuine transatlantic disagreement · ESUR
- ACR-SPR Practice Parameter for the Use of Intravascular Contrast Media · Other
- Behrendt FF et al. Peripheral intravenous power injection of iodinated contrast media through 22G and 20G cannulas: can high flow rates be achieved safely? A clinical feasibility study. · Primary literature
- Pressure injectors for radiologists: a review — extravasation incidence and catheter/flow-rate relationships · Primary literature
Implemented from the cited published sources. Educational and workflow support only; confirm against current guidelines and local policy before clinical use.